References of "Zegels, Brigitte"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailStrontium ranelate: new data on fracture prevention and mechanisms of action.
Reginster, Jean-Yves ULg; Deroisy, Rita ULg; Neuprez, Audrey et al

in Current Osteoporosis Reports (2009), 7(3), 96-102

Osteoporosis treatments need to combine an unequivocally demonstrated reduction of fractures, at various skeletal sites, long-term safety, and a user-friendly profile that optimizes therapeutic adherence ... [more ▼]

Osteoporosis treatments need to combine an unequivocally demonstrated reduction of fractures, at various skeletal sites, long-term safety, and a user-friendly profile that optimizes therapeutic adherence. Strontium ranelate is the first compound to simultaneously decrease bone resorption and stimulate bone formation. Its anti-fracture efficacy at various skeletal sites has been established for as long as 5 years through studies of the highest methodological standards. Increases in bone mineral density observed after 1 year of treatment are predictive of the long-term fracture efficacy, suggesting for the first time in osteoporosis that bone densitometry can be used as a monitoring tool. Due to a positive risk/benefit ratio, strontium ranelate is now considered as a first-line treatment in the management of osteoporosis. [less ▲]

Detailed reference viewed: 37 (1 ULg)
Full Text
Peer Reviewed
See detailPlace of residence as a risk factor for hip fracture? A case-control 3-year study
Bruyère, Olivier ULg; Pieck, C.; Hiligsmann, Mickaël ULg et al

in Annals of the Rheumatic Diseases (2008, June), 67(Suppl.II), 428

Detailed reference viewed: 12 (5 ULg)
Full Text
Peer Reviewed
See detailPlace of residence as a risk factor for hip fracture? A case-control 3-year study
Bruyère, Olivier ULg; Pieck, C.; Hiligsmann, Mickaël ULg et al

in Osteoporosis International (2008, April), 19(Suppl.1), 200

Detailed reference viewed: 9 (4 ULg)
Full Text
Peer Reviewed
See detailRole of Biochemical Markers of Bone Turnover as Prognostic Indicator of Successful Osteoporosis Therapy
Reginster, Jean-Yves ULg; Collette, Julien ULg; Neuprez, Audrey et al

in BONE (2008), 42

Most of the currently available anti-osteoporosis medications promptly and significantly influence the rate of bone turnover. Biochemical markers of bone turnover now provide a high sensitivity to change ... [more ▼]

Most of the currently available anti-osteoporosis medications promptly and significantly influence the rate of bone turnover. Biochemical markers of bone turnover now provide a high sensitivity to change, allowing the detection of these bone turnover changes within a couple of weeks. Since the anti-fracture efficacy of inhibitors of bone resorption or stimulators of bone formation appears to be largely independent of baseline bone turnover, biochemical markers do not appear to play a significant role in the selection of one particular drug, for an individual patient. However, there are consistent data showing that short-term changes in biochemical markers of bone turnover may be significant predictors of future changes in bone mineral density or fracture reduction, hence suggesting that bone turnover markers play a significant role in the monitoring of anti-osteoporosis therapy. [less ▲]

Detailed reference viewed: 76 (11 ULg)
Full Text
Peer Reviewed
See detailSymptom and structure modifying properties of chondroitin sulfate in osteoarthritis
Reginster, Jean-Yves ULg; Heraud, F.; Zegels, Brigitte ULg et al

in Mini Reviews in Medicinal Chemistry (2007), 7(10), 1051-1061

Chondroitin sulfate (CS) is a complex carbohydrate polymer with variable sulfation which impacts function. CS exhibits a wide range of biological activities. Many experimental and clinical data are ... [more ▼]

Chondroitin sulfate (CS) is a complex carbohydrate polymer with variable sulfation which impacts function. CS exhibits a wide range of biological activities. Many experimental and clinical data are available, affirming that CS represents an effective and safe symptomatic treatment of osteoarthritis (OA) with delayed and sustained effects. [less ▲]

Detailed reference viewed: 28 (7 ULg)
Full Text
Peer Reviewed
See detailComprehensive therapy in osteoporosis using a single drug: From ADFR to strontium ranelate
Manette, Christine ULg; Collette, Julien ULg; Sarlet, Nathalie ULg et al

in Current Medicinal Chemistry (2006), 13(13), 1585-1590

In vitro, strontium ranelate increases collagen and non-collagenic proteins synthesis by mature osteoblast enriched cells. The effects of strontium ranelate on bone formation were confirmed as the drug ... [more ▼]

In vitro, strontium ranelate increases collagen and non-collagenic proteins synthesis by mature osteoblast enriched cells. The effects of strontium ranelate on bone formation were confirmed as the drug enhanced preosteoblastic cell replication. In the isolated rat osteoclast, a preincubation of bone slices with strontium ranclate induced a dose-dependent inhibition of the bone resorbing activity of treated rat osteoclast. Strontium ranelate dose-dependently inhibited preosteoclast differentiation. In a phase 11 dose ranging trial Strontium ranclate (500 mg. 1000 mg, 2000 mg/day) or placebo were given to 353 postmenopausal women with prevalent vertebral osteoporosis. At the conclusion of this 2-year study. the annual increase in lumbar BMD of the group receiving 2000 mg of strontium ranclate was + 7.3%. a significant increase in bone alkaline phosphatase, over a 6-month period and a significant decrease in N-telopeptide crosslinks throughout the 2-year period were seen. During the second year of treatment, the dose of 2000 mg was associated with a 44% reduction in the number of patients experiencing a new vertebral deformity. The primary analysis of the SOTI study, evaluatine the effect of strontium ranelate 2000 mg on vertebral fracture rates, revealed a 41% reduction in the relative risk of patient experiencing a first new vertebral fracture with strontium ranelate throughout the 3-year study. The TROPOS study showed a significant reduction in the risk of experiencing a first non-vertebral fracture by 16% in the group treated with strontium ranclate throughout the 3-year study. A reduction in the risk of experiencing a hip fracture by 36% was also demonstrated in the patients at high risk of hip fracture (age >= 74 years and Femoral Neck T score <=-2.4 according to NHANES normative value). [less ▲]

Detailed reference viewed: 39 (2 ULg)
Full Text
Peer Reviewed
See detailNew serum biochemical markers (Coll 2-1 and Coll 2-1 NO2) for studying oxidative-related type II collagen network degradation in patients with osteoarthritis and rheumatoid arthritis
Deberg, Michelle ULg; Labasse, Alain ULg; Christgau, S. et al

in Osteoarthritis and Cartilage (2005), 13(3), 258-265

Objective: Protein nitration is a prominent feature of inflammatory processes in the joint. We have developed immunoassays specific for a peptide of the alpha-helical region of type II collagen (108 ... [more ▼]

Objective: Protein nitration is a prominent feature of inflammatory processes in the joint. We have developed immunoassays specific for a peptide of the alpha-helical region of type II collagen (108)HRGYPGLDG(116) (Coll 2-1) and its nitrated form (108)HRGY(NO2)PGLDG(116) (Coll 2-1 NO2) in biological fluids. Design: Coll 2-1 and Coll 2-1 NO2 peptides were injected into rabbits. Two antisera (D3 and D37) were selected for their specificity and affinity and used to develop specific immunoassays. Coll 2-1 and Coll 2-1 NO2 were measured in sera of 242 healthy subjects (N), 67 patients with primary knee osteoarthritis (OA) and 19 patients with rheumatoid arthritis (RA). Results: In healthy subjects, Coll 2-1 and Coll 2-1 NO2 concentrations were 125.13 +/- 3.71 nM and 0.16 +/- 0.08 nM, respectively. In OA and RA, Coll 2-1 and Coll 2-1 NO2 serum levels were found to be significantly increased compared to controls of the same range of age (Coll 2-1: OA: 200.80 +/- 8.98 nM, RA: 172.30 +/- 19.05 nM, normal: 126.60 +/- 6.70 nM and Coll 2-1 NO2: OA: 0.26 +/- 0.02, RA: 0.38 +/- 0.05, normal: 0.12 +/- 0.01 nM). Coll 2-1 NO2 levels were significantly more elevated in RA than in OA patients (P < 0.05). As a consequence, the ratio Coll 2-1 NO2/Coll 2-1 was 1.6 times higher in RA than in OA subjects. No relationship was found between the radiological OA severity and the levels of Coll 2-1 and Coll 2-1 NO2 in serum. Coll 2-1 NO2, but not Coll 2-1, was correlated with C-reactive protein in the sera of OA and RA patients. Conclusions: The determination of both Coll 2-1 and Coll 2-1 NO2 in serum of arthritic patients seems to be a promising useful tool for the detection of oxidative-related cartilage degradation episode. Further, these markers could be helpful for monitoring the effects of anti-inflammatory or antioxidant drugs on cartilage degradation. (c) 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved. [less ▲]

Detailed reference viewed: 53 (5 ULg)
Full Text
Peer Reviewed
See detailEvaluation of the relationship between IGF-1, IGF-BP3, BMD and age in men presenting at a multiple risk detection campaign
Hanssens, L.; Tancredi, Annalisa ULg; DeCeulaer, F. et al

in Osteoporosis International (2004, May), 15(Suppl.1), 48-49

Detailed reference viewed: 13 (7 ULg)
Full Text
Peer Reviewed
See detailReduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk
Reginster, Jean-Yves ULg; Sarkar, S.; Zegels, Brigitte ULg et al

in BONE (2004), 34(2), 344-351

In the Multiple Outcomes of Raloxifene Evaluation (MORE) trial, 7705 postmenopausal women with osteoporosis, defined by low bone mineral density and/or prevalent vertebral fractures (VF), were randomized ... [more ▼]

In the Multiple Outcomes of Raloxifene Evaluation (MORE) trial, 7705 postmenopausal women with osteoporosis, defined by low bone mineral density and/or prevalent vertebral fractures (VF), were randomized to placebo or raloxifene (60 or 120 mg/day). All women received daily calcium (500 mg) and vitamin D (400-600 IU) supplements. Our previous analyses found that changes in BMD and biochemical markers of bone turnover are poorly predictive of the reduction in VF risk observed with raloxifene. This present study evaluated the effects of raloxifene on type I procollagen N-terminal propeptide (PINP), a new marker of bone turnover. Logistic regression analysis models evaluated the relationships between the changes at 1 year in PINP, serum osteocalcin (OC), bone-specific alkaline phosphatase (BSAP), and urinary excretion of type I collagen C-telopeptide fragments normalized to creatinine (CTx/Cr), and the risk of new VF at 3 years for placebo and pooled raloxifene. A subset of 967 women (mean age = 68 years) from the MORE cohort had PINP, OC, BSAP, and CTx evaluated at baseline. Both doses of raloxifene significantly decreased (P < 0.001) all biochemical markers of bone turnover from baseline. Compared to baseline, PINP levels were decreased by medians of 11.0% and 40.8% in the placebo and pooled raloxifene groups, respectively. In addition, the placebo and pooled raloxifene groups decreased serum OC by 8.5% and 31.8%, BSAP by 15.8% and 34.6%, and urinary CTx/Cr excretion by 5.6% and 46.5%, respectively, from baseline. In the pooled raloxifene group, the logistic regression relationship between 3-year VF risk and 1-year percentage change for each biochemical marker was statistically significant with PINP (slope estimate = 0.0085, P = 0.009), OC (slope estimate = 0.0068, P = 0.035), and BSAP (slope estimate = 0.0056, P = 0.039), but not with CTx/Cr (slope estimate = 0.0027, P = 0.192). Furthermore, the percent decrease in PINP at 1 year could account for 28% of the total reduction in vertebral fracture risk. In conclusion, a 1-year decrease in PINP, BSAP, or OC, but not CTx/Cr, may be predictive of the 3-year VF risk reduction with raloxifene therapy in this subset of postmenopausal women with osteoporosis. [less ▲]

Detailed reference viewed: 24 (5 ULg)
Full Text
Peer Reviewed
See detailEvaluation of the relationship between IGF-I, IGF-BP3, BMD and age in men presenting at a multiple risk detection campaign
Hanssens, L.; Tancredi, Annalisa ULg; De Ceulaer, F. et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 90-91

Detailed reference viewed: 20 (7 ULg)
Peer Reviewed
See detailDo utility values and willingness to pay suitably reflect health outcome in hip and knee osteoarthritis? A comparative analysis with the WOMAC index
Ethgen, Olivier ULg; Tancredi, Annalisa ULg; Lejeune, Emmanuelle ULg et al

in Journal of Rheumatology (2003), 30(11), 2452-2459

Objective. To establish whether health utility (time trade-off, TTO) and willingness to pay (WTP) values reflect clinical health outcome as evaluated by the Western Ontario McMaster Universities ... [more ▼]

Objective. To establish whether health utility (time trade-off, TTO) and willingness to pay (WTP) values reflect clinical health outcome as evaluated by the Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) in hip and knee osteoarthritis (OA). Methods. One hundred twenty-eight patients with OA attending a specialized arthritis clinic were interviewed about their socioeconomic characteristics and administered the TTO technique and the WOMAC. Their WTP for 2 hypothetical anti-osteoarthritic drugs was also investigated: the first drug was said to provide a significant improvement in WOMAC dimensions and the second a complete cure of the disease. WTP was elicited by both discrete-choice and bidding game methods. Results. Answer rates were 89.1% for TTO, 98.4% for discrete-choice WTP for both scenarios, and 89.8% and 85.2% for bidding game WTP in the relief and the cure scenario, respectively. The mean TTO utility value was 0.84 (standard deviation 0.20). In discrete-choice, those accepting the bid had higher monthly income (euro 1536.5 vs euro 1060. 1, p < 0.001, for the relief scenario and euro 1449.3 vs euro 1071.6, p < 0.001, for the cure scenario). With the bidding game format, WTP was positively correlated with income in both scenarios (r = 0.56, r = 0.55, p < 0.001). WTP measures differed equally between education and socioeconomic groups with those in favored groups consistently reporting higher WTP (Kruskal-Wallis tests statistics ranging from p < 0.01 to p < 0.001). Except for stiffness, WOMAC dimensions were correlated in the expected direction with TTO values (r = -0.27, p < 0.01 for pain and r = -0.36, r = -0.34, p < 0.001 for physical function and total score, respectively). Conclusion. Whereas they showed good feasibility, WTP measures poorly reflected clinical condition and were mainly related to economic status and ability to pay. TTO was correlated with the WOMAC dimensions and may be considered closer to clinical situations than WTP. However, concern arises regarding the homogeneity of the study sample in terms of clinical severity, which may have precluded the identification of a relationship between WTP and clinical status. [less ▲]

Detailed reference viewed: 53 (9 ULg)
Full Text
Peer Reviewed
See detailCartilage degradation and oxidative damage in OA and RA patients
Deberg, Michelle ULg; Labasse, Alain ULg; Christgau, S. et al

in Osteoporosis International (2003, November), 14(Suppl. 7), 44-45

Detailed reference viewed: 15 (4 ULg)
Full Text
Peer Reviewed
See detailSubchondral tibial bone mineral density predicts future joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis
Bruyère, Olivier ULg; Dardenne, Charles-Bernard ULg; Lejeune, Eric ULg et al

in BONE (2003), 32(5), 541-545

Preliminary studies have shown that dual-energy X-ray absorptiometry (DXA) produces images of sufficient quality for a precise and accurate measurement at density of the subchondral bone. The objective of ... [more ▼]

Preliminary studies have shown that dual-energy X-ray absorptiometry (DXA) produces images of sufficient quality for a precise and accurate measurement at density of the subchondral bone. The objective of this study was to investigate the relationship between baseline subchondral tibial bone mineral density (BMD) and joint space narrowing observed after 1 year at the medial femoro-tibial compartment of the knee joint. Fifty-six consecutive patients, from both genders, with knee osteoarthritis diagnosed according to the American College of Rheumatology criteria, were included in the study. Radiographic posteroanterior views were taken, at baseline and after 1 year of follow-up. Minimum joint space width (JSW) measurement, at the medial femoro-tibial joint, was performed with a 0.1-mm graduated magnifying lens. Baseline BMD of the subchondral tibial bone was assessed by DXA. The mean +/- SD age of the patients was 65.3 +/- 8.7 years, with a body mass index of 28.0 +/- 4.9 kg/m(2). The minimum JSW was 3.5 +/- 1.5 mm and the mean BMD of the subchondral bone was 0.848 +/- 0.173 g/cm(2). There was a significant negative correlation between subchondral BMD and 1-year changes in minimum JSW (r = -0.43, p = 0.02). When performing a multiple regression analysis with age, sex, body mass index, and minimum JSW at baseline as concomitant variables, BMD of the subchondral bone as well as JSW at baseline were independent predictors of 1-year changes in JSW (p = 0.02 and p = 0.005, respectively). Patients in the lowest quartile of baseline BMD (<0.73 g/cm(2)) experienced less joint space narrowing than those in the highest BMD quartile (>0.96 g/cm(2)) (+0.61 +/- 0.69 turn versus -0.13 +/- 0.27 mm; p = 0.03). Assessment of BMD of the subchondral tibial bone is significantly correlated with future joint space narrowing and could be used as a predictor of knee osteoarthritis progression. (C) 2003 Elsevier Science (USA). All rights reserved. [less ▲]

Detailed reference viewed: 54 (5 ULg)
Full Text
Peer Reviewed
See detailSubchondral tibial bone mineral density predicts joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis
Bruyère, Olivier ULg; Lambert, V.; Dardenne, C. et al

in Osteoporosis International (2002, November), 13(Suppl.3), 51-52

Detailed reference viewed: 9 (3 ULg)
Full Text
Peer Reviewed
See detailA comparative analysis between the time trade-off and the willingness to pay approaches in hip and knee osteoarthritis
Ethgen, Olivier ULg; Tancredi, Annalisa ULg; Lejeune, Eric ULg et al

in Osteoporosis International (2002, November), 13(Suppl. 3), 47

Detailed reference viewed: 32 (8 ULg)
Full Text
Peer Reviewed
See detailDo willingness to pay and time trade-off approaches suitably reflect health outcomes in hip and knee osteoarthritis?
Ethgen, Olivier ULg; Tancredi, Annalisa; Lejeune, Eric ULg et al

in Arthritis and Rheumatism (2002, September), 46(number 9 (suppl.)), 73

Detailed reference viewed: 8 (4 ULg)
Full Text
Peer Reviewed
See detailSubchondral tibial bone mineral density predicts joint space narrowing at the medial femoro-tibial compartment in patients with knee osteoarthritis
Bruyère, Olivier ULg; LAMBERT, Virginie ULg; Dardenne, Charles et al

in Arthritis and Rheumatism (2002, September), 16(number 9 (suppl.)), 154

Detailed reference viewed: 6 (0 ULg)
Full Text
Peer Reviewed
See detailDevelopment and assessment of the Osteoporosis Index of Risk (OSIRIS) to facilitate selection of women for bone densitometry
Sedrine, W. B.; Chevallier, T.; Zegels, Brigitte ULg et al

in Gynecological Endocrinology : The Official Journal of the International Society of Gynecological Endocrinology (2002), 16(3), 245-250

A simple questionnaire would be useful to identify individuals most in need of bone mineral density (BMD) testing. We designed a new predictive model and risk assessment instrument based on an extensive ... [more ▼]

A simple questionnaire would be useful to identify individuals most in need of bone mineral density (BMD) testing. We designed a new predictive model and risk assessment instrument based on an extensive review of the literature evaluating risk factors for osteoporosis, and tested its performance in a large cohort of postmenopausal women in whom BMD was measured by dual x-ray absorptiometry. In total, 1303 postmenopausal women from an outpatient osteoporosis clinic participated in this study. The Osteoporosis Index of Risk (OSIRIS) is based on four variables: age, body weight, current hormone replacement therapy use and history of previous low impact fracture. The sensitivity and specificity for an OSIRIS value of +1 were respectively 78.5% and 51.4%. The AUC under the ROC curve of OSIRIS was 0.71. Three categories were arbitrarily created using OSIRIS, with cutoff of +1 and -3. The low risk category (OSIRIS > +1) represented 41% of all women; only 7% of the women in this category had osteoporosis. The prevalence of osteoporosis was very high (66%) among the group at high risk (OSIRIS < -3 representing 15% of all women). The prevalence of osteoporosis was 39% in the intermediate risk group (-3 < OSIRIS < +1, 44% of all women). In conclusion, OSIRIS is a simple index based on four easy-to-collect variables from postmenopausal women, it shows a high degree of accuracy, and performed well for classifying the degree of risk of osteoporosis in western European women of Caucasian lineage. Based on this instrument it is possible to propose a strategy that would initiate treatment in women with very high risk, postpone BMD measurement in women with low risk and limit BMD measurement to women with intermediate risk of osteoporosis, this would spare more than 55% of the densitometry bill compared with a mass screening scenario. [less ▲]

Detailed reference viewed: 11 (2 ULg)
Full Text
Peer Reviewed
See detailInfluence of daily regimen calcium and vitamin D supplementation on parathyroid hormone secretion
Reginster, Jean-Yves ULg; Zegels, Brigitte ULg; Lejeune, Emmanuelle ULg et al

in Calcified Tissue International (2002), 70(2), 78-82

Calcium and vitamin D supplementation has been shown to reduce secondary hyperparathyroidism and play a role in the management of senile osteoporosis. In order to define the optimal regimen of calcium and ... [more ▼]

Calcium and vitamin D supplementation has been shown to reduce secondary hyperparathyroidism and play a role in the management of senile osteoporosis. In order to define the optimal regimen of calcium and vitamin D supplementation to produce the maximal inhibition of parathyroid hormone secretion, we have compared the administration of a similar amount of Ca and vitamin D, either as a single morning dose or split in two doses, taken 6 hours apart. Twelve healthy volunteers were assigned to three investigational procedures, at weekly intervals. After a blank control procedure, when they were not exposed to any drug intake, they received two calcium-vitamin D supplement regimens including either two doses of Orocal D3 (500 mg Ca and 400 IU vitamin D) 6 hours apart or one water-soluble effervescent powder pack of Cacit D3 in a single morning dose (1000 mg Ca and 880 IU vitamin D). During the three procedures (control and the two calcium-vitamin D supplementations), venous blood was drawn every 60 minutes for up to 9 hours, for serum Ca and serum PTH measurements. The order of administration of the two Ca and vitamin D supplementation sequences was allocated by randomization. No significant changes in serum Ca were observed during the study. During the 6 hours following Ca and vitamin D supplementation, a statistically significant decrease in serum PTH was observed with both regimens, compared with baseline and with the control procedure. Over this period of time, no differences were observed between the two treatment regimens. However, between the sixth and the ninth hour, serum PTH levels were still significantly decreased compared with baseline with split dose Orocal D3 administration, while they returned to baseline value with the Cacit D3 preparation. During this period, the percentage decrease in serum PTH compared with baseline was significantly more pronounced with Orocal D3 than with Cacit D3 (P = 0.0021). We therefore conclude that the administration of two doses of 500 mg of calcium and 400 IU of vitamin D3 6 hours apart provides a more prolonged decrease in serum PTH levels than the administration of the same total amount of Ca and vitamin D as a single morning dose in young healthy volunteers. This might have implications in terms of protection of the skeleton against secondary hyperparathyroidism and increased bone resorption and turnover in elderly subjects. [less ▲]

Detailed reference viewed: 58 (13 ULg)